Irinotecan (Valent Technologies)

N/A

Report date: 2026/03/11 20:02:12

Base Information

Drug NameIrinotecan (Valent Technologies)
Drug Alias NameIrinotecan HCl (Valent Technologies)OrotecanVAL-413IRN-IVPO
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA topoisomerase I inhibitors
TargetsDNA topoisomerase I
Therapy Area/IndicationsSolid tumoursNeuroblastomaMedulloblastoma +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesValent Technologies Inc
China Registration ClassN/A

Develop Information

Active CompaniesValent Technologies IncValent Technologies LlcMemorial Sloan Kettering Cancer Center
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeuroblastomaMedulloblastoma +[6] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A